Boehringer Ingelheim Biopharmaceuticals announces manufacturing agreement with Servier

Fri, 08/03/2012 - 10:25am
Boehringer Ingelheim

Ingelheim,Germany, 3 August 2012 – Boehringer Ingelheim announced today an agreement with Servier and its partner XOMA Corporation (Nasdaq: XOMA) to transfer XOMA’s technology and process for the commercial manufacture of gevokizumab, XOMA’s novel interleukin 1-beta (IL-1β) allosteric modulating antibody. Gevokizumab currently is in Phase 3 clinical development in patients with non-infectious uveitis (NIU). Upon completion of the transfer and the establishment of biological comparability, Boehringer Ingelheim is expected to produce gevokizumab at its facility in Biberach, Germany, for Servier’s commercial use. Servier and XOMA retain all rights to the development and commercialization of gevokizumab. Financial terms of the agreement were not disclosed.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.